Poor patient outcomes and relapse-free survival have been associated with MSLN expression in gastric, pancreatic and ovarian cancer, cholangiocarcinoma, breast cancer, endometrial cancer and lung cancer [8,9]. This evidence concerns the gene MSLN and ovarian cancer.